Man Group plc Makes New $73.09 Million Investment in United Therapeutics Corporation $UTHR

Man Group plc acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 134,890 shares of the biotechnology company’s stock, valued at approximately $73,087,000.

Several other hedge funds have also modified their holdings of the stock. BlackRock Inc. purchased a new position in United Therapeutics in the second quarter worth approximately $2,868,735,000. Wellington Management Group LLP increased its position in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. Jupiter Topco LLC acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at $450,140,000. Norges Bank acquired a new stake in shares of United Therapeutics in the 4th quarter valued at $293,418,000. Finally, Avoro Capital Advisors LLC lifted its position in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Up 1.1%

UTHR opened at $518.53 on Wednesday. The business’s 50 day moving average is $531.75 and its two-hundred day moving average is $538.30. The firm has a market cap of $22.24 billion, a price-to-earnings ratio of 18.55, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a 52 week low of $302.19 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the firm earned $6.41 EPS. Equities analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of analyst reports. Bank of America lowered their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. JPMorgan Chase & Co. lifted their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research report on Thursday, August 6th. Royal Bank Of Canada dropped their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $646.00.

Insider Activity

In other news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $23,631,280.08. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $511.97, for a total transaction of $4,863,715.00. Following the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $166,105,082.71. This trade represents a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 434,075 shares of company stock worth $233,340,010. Insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.